Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Preferred Stock Liabilities (2025)

Drugs Made In America Acquisition filings provide 1 years of Preferred Stock Liabilities readings, the most recent being $239.9 million for Q4 2025.

  • Quarterly Preferred Stock Liabilities changed N/A to $239.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $239.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $239.9 million for FY2025, N/A changed from the prior year.
  • Preferred Stock Liabilities hit $239.9 million in Q4 2025 for Drugs Made In America Acquisition, up from $237.6 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $239.9 million in Q4 2025 and bottomed at $232.7 million in Q1 2025.